Home › Linfoma a cellule B › Texas › Houston
Studi clinici su Linfoma a cellule B a Houston, TX
16 studi su Linfoma a cellule B cercano partecipanti presso sedi a Houston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
In reclutamentoStudio osservazionale
- Texas Children's Hospital, Houston
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
In reclutamentoFase 3
- Md Anderson Cancer Center, Houston
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
In reclutamentoFase 2
- MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
In reclutamentoFase 1
- MD Anderson Cancer Center, Houston
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
In reclutamentoFase 2
- M D Anderson Cancer Center, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
In reclutamentoFase 2
- Research Site, Houston
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
In reclutamentoFase 1/2
- The University of Texas Md Anderson Cancer Center, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
In reclutamentoFase 1/2
- Research Site, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
In reclutamentoFase 1
- Clinical Trial Site, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
In reclutamentoFase 1/2
- M D Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
In reclutamentoFase 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
In reclutamentoFase 1
- The University of Texas M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
In reclutamentoFase 2
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
In reclutamentoFase 1
- MD Anderson Cancer Center, Houston
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
In reclutamentoFase 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
In reclutamentoFase 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Studi su Linfoma a cellule B in altre città
- New York City, NY19 studi
- Chicago, IL12 studi
- Nashville, TN11 studi
- Philadelphia, PA11 studi
- Rochester, MN10 studi
- Baldwin Park, CA9 studi
- Milwaukee, WI9 studi
- Cleveland, OH9 studi
- Salt Lake City, UT8 studi
- Boston, MA8 studi
- Columbus, OH7 studi
- Pittsburgh, PA7 studi
Altri studi a Houston
- Cancro del polmone non a piccole cellule145 studi
- Cancro al seno126 studi
- Cancro (tutti i tipi)121 studi
- Cancro metastatico104 studi
- Cancro colorettale102 studi
- Cancro ovarico89 studi
- Leucemia mieloide acuta85 studi
- Cancro ai polmoni78 studi
- Cancro alla prostata76 studi
- Cancro dell'endometrio68 studi
- Cancro pancreatico61 studi
- Melanoma59 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.